These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 3134548)

  • 1. Meningococcal vaccines.
    Poolman JT
    J Med Microbiol; 1988 Jul; 26(3):170-2. PubMed ID: 3134548
    [No Abstract]   [Full Text] [Related]  

  • 2. No evidence for serosubtype-restricted protection among teenagers vaccinated with the Norwegian group B outer membrane vesicle vaccine.
    Wedege E; Nokleby H; Bjune G
    J Infect Dis; 1999 Jul; 180(1):242; author reply 242-3. PubMed ID: 10353890
    [No Abstract]   [Full Text] [Related]  

  • 3. Immunization with meningococcal outer-membrane protein vesicles containing lipooligosaccharide protects mice against lethal experimental group B Neisseria meningitidis infection and septic shock.
    Quakyi EK; Frasch CE; Buller N; Tsai CM
    J Infect Dis; 1999 Sep; 180(3):747-54. PubMed ID: 10438363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Vaccines against Neisseria meningitidis].
    Ferrón L; Criado MT; Ferreirós CM
    Enferm Infecc Microbiol Clin; 1992 May; 10(5):296-301. PubMed ID: 1391002
    [No Abstract]   [Full Text] [Related]  

  • 5. Vaccination against meningococcus in complement-deficient individuals.
    Morgan BP; Orren A
    Clin Exp Immunol; 1998 Dec; 114(3):327-9. PubMed ID: 9844038
    [No Abstract]   [Full Text] [Related]  

  • 6. Vaccines against meningococcal meningitis: current status.
    Epidemiol Bull; 1994 Jul; 15(2):13-5. PubMed ID: 8086300
    [No Abstract]   [Full Text] [Related]  

  • 7. A new variant of serosubtype P1.16 in Neisseria meningitidis from Norway, associated with increased resistance to bactericidal antibodies induced by a serogroup B outer membrane protein vaccine.
    Rosenqvist E; Høiby EA; Wedege E; Caugant DA; Frøholm LO; McGuinness BT; Brooks J; Lambden PR; Heckels JE
    Microb Pathog; 1993 Sep; 15(3):197-205. PubMed ID: 7505873
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of complement in anti-bacterial defence.
    D'Amelio R; Biselli R
    Ann Ital Med Int; 1994; 9(3):173-7. PubMed ID: 7946895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Meningococcal strains isolated from teenage patients during the serogroup B vaccination trial in Norway: serotyping, serosubtyping, immunotyping and clonal analysis.
    Frøholm LO; Caugant DA; Holten E; Høiby EA; Rosenqvist E; Wedege E
    NIPH Ann; 1991 Dec; 14(2):139-43; discussion 144-6. PubMed ID: 1812428
    [No Abstract]   [Full Text] [Related]  

  • 10. [Meningococcal meningitis: bacterial virulence, antibodies or complement?].
    Pujadas Capmany R; Jané Pesquer J
    Med Clin (Barc); 1984 Nov; 83(16):671-3. PubMed ID: 6439961
    [No Abstract]   [Full Text] [Related]  

  • 11. Outer-membrane-vesicle vaccines: old but not forgotten.
    Stephens DS
    Lancet Infect Dis; 2011 Jun; 11(6):421-2. PubMed ID: 21489883
    [No Abstract]   [Full Text] [Related]  

  • 12. Typing of group-B Neisseria meningitidis with monoclonal antibodies in the whole-cell ELISA.
    Abdillahi H; Poolman JT
    J Med Microbiol; 1988 Jul; 26(3):177-80. PubMed ID: 3134550
    [No Abstract]   [Full Text] [Related]  

  • 13. Outer membrane vesicles (OMVs) and detoxified lipooligosaccharide (dLOS) obtained from Brazilian prevalent N. meningitidis serogroup B strains protect mice against homologous and heterologous meningococcal infection and septic shock.
    Jessouroun E; da Silveira IF; Larangeira AP; Pereira S; Fernandes SA; Rabinovitch L; Frasch CE; Castro-Faria-Neto HC; Bozza PT
    Vaccine; 2004 Jun; 22(20):2617-25. PubMed ID: 15193387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Production and control of Neisseria meningitidis vaccines.
    Frasch CE
    Adv Biotechnol Processes; 1990; 13():123-45. PubMed ID: 2110462
    [No Abstract]   [Full Text] [Related]  

  • 15. Status of a group B Neisseria meningitidis vaccine.
    Frasch CE
    Eur J Clin Microbiol; 1985 Dec; 4(6):533-6. PubMed ID: 3937731
    [No Abstract]   [Full Text] [Related]  

  • 16. ABC of meningococcal diversity.
    Feavers IM
    Nature; 2000 Mar; 404(6777):451-2. PubMed ID: 10761900
    [No Abstract]   [Full Text] [Related]  

  • 17. Assessment of complement deficiency in patients with meningococcal disease in The Netherlands.
    Fijen CA; Kuijper EJ; te Bulte MT; Daha MR; Dankert J
    Clin Infect Dis; 1999 Jan; 28(1):98-105. PubMed ID: 10028078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis.
    Holst J; Martin D; Arnold R; Huergo CC; Oster P; O'Hallahan J; Rosenqvist E
    Vaccine; 2009 Jun; 27 Suppl 2():B3-12. PubMed ID: 19481313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bacterial outer membrane protein vaccines. The meningococcal example.
    Poolman JT
    Adv Exp Med Biol; 1996; 397():73-7. PubMed ID: 8718585
    [No Abstract]   [Full Text] [Related]  

  • 20. Review of meningococcal vaccines with emphasis on possible immunoprophylaxis of group B disease.
    Frøholm LO
    NIPH Ann; 1980 Dec; 3(2):67-74. PubMed ID: 6784045
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.